The efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study
RC48-ADC combined with ICIs demonstrated robust antitumor activity and a favorable safety profile in real-world mUTUC, particularly in selected patient groups. Further studies are needed to explore its potential in this high-risk population.
Authors
- Qi Tang (ORCID: https://orcid.org/0000-0002-2109-7935)
- Zejun Yan (ORCID: https://orcid.org/0000-0002-8138-459X)
- Minfeng Chen (ORCID: https://orcid.org/0000-0003-4200-3261)
- Jiwei Huang (ORCID: https://orcid.org/0000-0002-1463-670X)
- Qingwu Yang (ORCID: https://orcid.org/0000-0002-2596-2631)
- Jitao Wu (ORCID: https://orcid.org/0000-0002-7924-3923)
- Zhankui Jia (ORCID: https://orcid.org/0000-0001-9545-6163)
- Haibo Shen (ORCID: https://orcid.org/0000-0002-1183-6570)
- Hailong Hu (ORCID: https://orcid.org/0000-0001-8675-5524)
- Hai Bi (ORCID: https://orcid.org/0000-0002-6786-2081)
- Yige Bao (ORCID: https://orcid.org/0000-0003-4002-5467)
- Jianjun Ye
- Shicheng Yu (ORCID: https://orcid.org/0000-0002-3737-8010)
- Guoqing Ding (ORCID: https://orcid.org/0000-0003-3156-3618)
- Tao Zhang (ORCID: https://orcid.org/0000-0001-6643-4686)
- Shun Zhang (ORCID: https://orcid.org/0000-0002-0001-1880)
- Zheng Liu (ORCID: https://orcid.org/0000-0001-8445-1228)
- Wei Xiong (ORCID: https://orcid.org/0000-0003-1635-8173)
- Xiaoyi Hu (ORCID: https://orcid.org/0000-0002-7595-3004)
- Jun Xiao (ORCID: https://orcid.org/0000-0002-6142-9914)
- Weiping Huang (ORCID: https://orcid.org/0000-0002-7306-3550)
- Xuedong Wei (ORCID: https://orcid.org/0000-0003-2000-2620)
- Zhiyang Huang (ORCID: https://orcid.org/0000-0001-6677-068X)
- Cheoklong Ng
- Dan Xia (ORCID: https://orcid.org/0000-0002-5256-3900)
- Yichu Yuan
- Taile Jing (ORCID: https://orcid.org/0000-0002-0294-5652)
- Wei Xue (ORCID: https://orcid.org/0000-0003-3614-6194)
Institutions
- Qingdao University (CN)
- University of Science and Technology of China (CN)
- Central South University (CN)
- Shanghai Jiao Tong University (CN)
- Peking University (CN)
- Sichuan University (CN)
- Fudan University (CN)
- Renji Hospital (CN)
- XinHua Hospital (CN)
- Yuhuangding Hospital (CN)
- West China Hospital of Sichuan University (CN)
- Tongren Hospital (CN)
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
- Zhongshan Hospital (CN)
- Peking University First Hospital (CN)
- Ningbo University Affiliated Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Xiangya Hospital Central South University (CN)
- Tongji Hospital (CN)
- Ningbo First Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-09-13
- DOI
- https://doi.org/10.1007/s00262-025-04154-5
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.02